메뉴 건너뛰기




Volumn 17, Issue SUPPL.1, 2008, Pages

The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer

Author keywords

Aromatase inhibitor(s); Breast cancer; Disease free survival; Distant metastases; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; ESTRONE SULFATE; EXEMESTANE; FORMESTANE; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

EID: 38949197079     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(08)70004-3     Document Type: Article
Times cited : (6)

References (51)
  • 1
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 2
    • 33947246190 scopus 로고    scopus 로고
    • Predictors of early recurrence in postmenopausal women with operable breast cancer
    • Abstract 2091.
    • Mansell J., Monypenny I., Skene A., et al. Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Res Treat 100 Suppl 1 (2006) S111 Abstract 2091.
    • (2006) Breast Cancer Res Treat , vol.100 , Issue.SUPPL. 1
    • Mansell, J.1    Monypenny, I.2    Skene, A.3
  • 3
    • 14644413523 scopus 로고    scopus 로고
    • The effect of locoregional recurrence on survival and distant metastasis after conservative treatment for invasive breast carcinoma
    • Monteiro Grillo I., Jorge M., Marques Vidal P., Ortiz M., and Ravasco P. The effect of locoregional recurrence on survival and distant metastasis after conservative treatment for invasive breast carcinoma. Clin Oncol (R Coll Radiol) 17 (2005) 111-117
    • (2005) Clin Oncol (R Coll Radiol) , vol.17 , pp. 111-117
    • Monteiro Grillo, I.1    Jorge, M.2    Marques Vidal, P.3    Ortiz, M.4    Ravasco, P.5
  • 4
    • 33646758467 scopus 로고    scopus 로고
    • Breast cancer recurrence and related mortality in US pts with early breast cancer
    • Abstract 738.
    • Lamerato L., Havstad S., Gandhi S., Jones D., and Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol 23 16S (2005) 62S Abstract 738.
    • (2005) J Clin Oncol , vol.23 , Issue.16 S
    • Lamerato, L.1    Havstad, S.2    Gandhi, S.3    Jones, D.4    Chlebowski, R.5
  • 5
    • 0037157603 scopus 로고    scopus 로고
    • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of theATAC randomised trial
    • ATAC Trialists' Group
    • Baum M., Budzar A., Cuzick J., et al., ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of theATAC randomised trial. Lancet 359 (2002) 2131-2139
    • (2002) Lancet , vol.359 , pp. 2131-2139
    • Baum, M.1    Budzar, A.2    Cuzick, J.3
  • 6
    • 0142181118 scopus 로고    scopus 로고
    • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses
    • The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group
    • Baum M., Buzdar A., Cuzick J., et al., The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
    • (2003) Cancer , vol.98 , pp. 1802-1810
    • Baum, M.1    Buzdar, A.2    Cuzick, J.3
  • 7
    • 11444251764 scopus 로고    scopus 로고
    • Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    • ATAC Trialists' Group
    • Howell A., Cuzick J., Baum M., et al., ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
    • (2005) Lancet , vol.365 , pp. 60-62
    • Howell, A.1    Cuzick, J.2    Baum, M.3
  • 8
    • 29544433211 scopus 로고    scopus 로고
    • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    • for the Breast International Group (BIG) 1-98 Collaborative Group
    • Thürlimann B., Keshaviah A., Coates A., et al., for the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
    • (2005) N Engl J Med , vol.353 , pp. 2747-2757
    • Thürlimann, B.1    Keshaviah, A.2    Coates, A.3
  • 9
    • 33947510501 scopus 로고    scopus 로고
    • Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
    • Coates A., Keshaviah A., Thürlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
    • (2007) J Clin Oncol , vol.25 , pp. 486-492
    • Coates, A.1    Keshaviah, A.2    Thürlimann, B.3
  • 10
    • 33645950746 scopus 로고    scopus 로고
    • Exemestane as adjuvant treatment of early breast cancer: Intergroup Exemestane Study/Tamoxifen Exemestane Adjuvant Multicenter trials
    • Jones S. Exemestane as adjuvant treatment of early breast cancer: Intergroup Exemestane Study/Tamoxifen Exemestane Adjuvant Multicenter trials. Clin Breast Cancer 6 Suppl 2 (2006) S41-S44
    • (2006) Clin Breast Cancer , vol.6 , Issue.SUPPL. 2
    • Jones, S.1
  • 11
    • 10744223655 scopus 로고    scopus 로고
    • A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    • Coombes R., Hall E., Gibson L., et al., Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
    • (2004) N Engl J Med , vol.350 , pp. 1081-1092
    • Coombes, R.1    Hall, E.2    Gibson, L.3
  • 12
    • 33751321384 scopus 로고    scopus 로고
    • Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early- stage breast cancer: a meta-analysis
    • Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early- stage breast cancer: a meta-analysis. Lancet Oncol 7 (2006) 991-996
    • (2006) Lancet Oncol , vol.7 , pp. 991-996
    • Jonat, W.1    Gnant, M.2    Boccardo, F.3
  • 13
    • 7444259675 scopus 로고    scopus 로고
    • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    • Goss P., Ingle J., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
    • (2003) N Engl J Med , vol.349 , pp. 1793-1802
    • Goss, P.1    Ingle, J.2    Martino, S.3
  • 14
    • 24744450378 scopus 로고    scopus 로고
    • Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
    • Goss P., Ingle J., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
    • (2005) J Natl Cancer Inst , vol.97 , pp. 1262-1271
    • Goss, P.1    Ingle, J.2    Martino, S.3
  • 15
    • 34247864457 scopus 로고    scopus 로고
    • Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33
    • Abstract 49.
    • Mamounas E., Jeong J.-H., Wickerham L., et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 100 Suppl 1 (2006) S22 Abstract 49.
    • (2006) Breast Cancer Res Treat , vol.100 , Issue.SUPPL. 1
    • Mamounas, E.1    Jeong, J.-H.2    Wickerham, L.3
  • 16
    • 23444435619 scopus 로고    scopus 로고
    • Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)
    • Abstract 526.
    • Jakesz R., Samonigg H., Greil R., et al., on behalf of the ABCSG. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 23 16 Suppl (2005) 10S Abstract 526.
    • (2005) J Clin Oncol , vol.23 , Issue.16 SUPPL
    • Jakesz, R.1    Samonigg, H.2    Greil, R.3
  • 17
    • 33846545851 scopus 로고    scopus 로고
    • Survival and safety of exemestane versus tamoxifen after 2 3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
    • Coombes R., Kilburn L., Snowdon C., et al., Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2 3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
    • (2007) Lancet , vol.369 , pp. 559-570
    • Coombes, R.1    Kilburn, L.2    Snowdon, C.3
  • 18
    • 33751241251 scopus 로고    scopus 로고
    • AstraZeneca Pharmaceuticals LP, Wilmington, DE
    • Arimidex package insert (2005), AstraZeneca Pharmaceuticals LP, Wilmington, DE
    • (2005) Arimidex package insert
  • 19
    • 34948831626 scopus 로고    scopus 로고
    • Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) data reported on behalf of the ATAC ("Arimidex", tamoxifen, alone or in Combination) Trialists' group
    • Abstract 243PD.
    • Houghton J. Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) data reported on behalf of the ATAC ("Arimidex", tamoxifen, alone or in Combination) Trialists' group. Ann Oncol 17 Suppl 9 (2006) ix94 Abstract 243PD.
    • (2006) Ann Oncol , vol.17 , Issue.SUPPL. 9
    • Houghton, J.1
  • 20
    • 34249292099 scopus 로고    scopus 로고
    • Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
    • Mauriac L., Keshaviah A., Debled M., et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18 (2007) 859-867
    • (2007) Ann Oncol , vol.18 , pp. 859-867
    • Mauriac, L.1    Keshaviah, A.2    Debled, M.3
  • 21
    • 35548937114 scopus 로고    scopus 로고
    • Comparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with 5 years of tamoxifen (TAM) in postmenopausal women with early breast cancer (EBC)
    • Abstract 2084.
    • Vakaet L., and Buyse M. Comparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with 5 years of tamoxifen (TAM) in postmenopausal women with early breast cancer (EBC). Breast Cancer Res Treat 100 Suppl 1 (2006) S108-S109 Abstract 2084.
    • (2006) Breast Cancer Res Treat , vol.100 , Issue.SUPPL. 1
    • Vakaet, L.1    Buyse, M.2
  • 22
    • 38949204962 scopus 로고    scopus 로고
    • Rugo HS, Kaura S, Dranitsaris G. The number needed to treat (NNT) as a measure of drug efficacy: the case of aromatase inhibitors (AIs) in post menopausal women with early breast cancer. Presented at the 10th International Conference: Primary Therapy of Early Breast Cancer; March 14 17, 2007; St. Gallen, Switzerland. Abstract 170.
    • Rugo HS, Kaura S, Dranitsaris G. The number needed to treat (NNT) as a measure of drug efficacy: the case of aromatase inhibitors (AIs) in post menopausal women with early breast cancer. Presented at the 10th International Conference: Primary Therapy of Early Breast Cancer; March 14 17, 2007; St. Gallen, Switzerland. Abstract 170.
  • 23
    • 33845283976 scopus 로고    scopus 로고
    • The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8
    • Abstract 13.
    • Jakesz R., Gnant M., Greil R., et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 94 Suppl 1 (2005) S10 Abstract 13.
    • (2005) Breast Cancer Res Treat , vol.94 , Issue.SUPPL. 1
    • Jakesz, R.1    Gnant, M.2    Greil, R.3
  • 25
    • 35548998081 scopus 로고    scopus 로고
    • Letrozole is more cost- effective than tamoxifen as early adjuvant therapy in multiple sub-groups of postmenopausal women with early breast cancer: the UK perspective
    • Abstract 5052.
    • Karnon J., Kaura S., and di Trapani F. Letrozole is more cost- effective than tamoxifen as early adjuvant therapy in multiple sub-groups of postmenopausal women with early breast cancer: the UK perspective. Breast Cancer Res Treat 100 Suppl 1 (2006) S230 Abstract 5052.
    • (2006) Breast Cancer Res Treat , vol.100 , Issue.SUPPL. 1
    • Karnon, J.1    Kaura, S.2    di Trapani, F.3
  • 26
    • 38949133121 scopus 로고    scopus 로고
    • Karnon J, di Tripani F, Kaura S. Comparison of the cost per distant disease-free year gained of upfront letrozole or anastrozole, or switched exemestane vs tamoxifen for early breast cancer in hormone- receptor positive a(HR+) postmenopausal women: the UK perspective. Presented at the 10th International Conference: Primary Therapy of Early Breast Cancer; March 14 17, 2007; St. Gallen, Switzerland. Abstract 179.
    • Karnon J, di Tripani F, Kaura S. Comparison of the cost per distant disease-free year gained of upfront letrozole or anastrozole, or switched exemestane vs tamoxifen for early breast cancer in hormone- receptor positive a(HR+) postmenopausal women: the UK perspective. Presented at the 10th International Conference: Primary Therapy of Early Breast Cancer; March 14 17, 2007; St. Gallen, Switzerland. Abstract 179.
  • 27
    • 2442684453 scopus 로고    scopus 로고
    • Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion- negative early breast cancers without adjuvant systemic therapies
    • Chia S., Speers C., Bryce C., Hayes M., and Olivotto I. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion- negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22 (2004) 1630-1637
    • (2004) J Clin Oncol , vol.22 , pp. 1630-1637
    • Chia, S.1    Speers, C.2    Bryce, C.3    Hayes, M.4    Olivotto, I.5
  • 28
    • 33846550085 scopus 로고    scopus 로고
    • Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen
    • Kennecke H., Olivotto I., Speers C., et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18 (2007) 45-51
    • (2007) Ann Oncol , vol.18 , pp. 45-51
    • Kennecke, H.1    Olivotto, I.2    Speers, C.3
  • 30
    • 38949159753 scopus 로고    scopus 로고
    • Peto R, Davies C; on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results. Presented at the 30th Annual San Antonio Breast Cancer Symposium; December 13 16, 2007; San Antonio, Texas. Abstract 48.
    • Peto R, Davies C; on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results. Presented at the 30th Annual San Antonio Breast Cancer Symposium; December 13 16, 2007; San Antonio, Texas. Abstract 48.
  • 31
    • 0035795683 scopus 로고    scopus 로고
    • Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
    • Fisher B., Dignam J., Bryant J., and Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 (2001) 684-690
    • (2001) J Natl Cancer Inst , vol.93 , pp. 684-690
    • Fisher, B.1    Dignam, J.2    Bryant, J.3    Wolmark, N.4
  • 32
    • 38949161221 scopus 로고    scopus 로고
    • Pater J, Tu D, Shepherd L, Ingle JN, Goss PE. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat 2007 May 3 [Epub ahead of print].
    • Pater J, Tu D, Shepherd L, Ingle JN, Goss PE. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat 2007 May 3 [Epub ahead of print].
  • 33
    • 33749078918 scopus 로고    scopus 로고
    • Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding
    • Abstract 550.
    • Robert N., Goss P., Ingle J., et al. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. J Clin Oncol 24 18S (2006) 15s Abstract 550.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S
    • Robert, N.1    Goss, P.2    Ingle, J.3
  • 34
    • 0035038371 scopus 로고    scopus 로고
    • Neoadjuvant therapy in breast cancer: can we define its role?
    • Aapro M. Neoadjuvant therapy in breast cancer: can we define its role?. Oncologist 6 (2001) 36-39
    • (2001) Oncologist , vol.6 , pp. 36-39
    • Aapro, M.1
  • 35
    • 24644490871 scopus 로고    scopus 로고
    • Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
    • IMPACT Trialists Group
    • Smith I., Dowsett M., Ebbs S., et al., IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 (2005) 5108-5116
    • (2005) J Clin Oncol , vol.23 , pp. 5108-5116
    • Smith, I.1    Dowsett, M.2    Ebbs, S.3
  • 36
    • 33646371731 scopus 로고    scopus 로고
    • Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial
    • Cataliotti L., Buzdar A., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 106 (2006) 2095-2103
    • (2006) Cancer , vol.106 , pp. 2095-2103
    • Cataliotti, L.1    Buzdar, A.2    Noguchi, S.3
  • 37
    • 0035692576 scopus 로고    scopus 로고
    • Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study
    • Letrozole Neo-Adjuvant Breast Cancer Study Group
    • Eiermann W., Paepke S., Appfelstaedt J., et al., Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 (2001) 1527-1532
    • (2001) Ann Oncol , vol.12 , pp. 1527-1532
    • Eiermann, W.1    Paepke, S.2    Appfelstaedt, J.3
  • 38
    • 0032974458 scopus 로고    scopus 로고
    • Biology of aromatase inhibitors: pharmacology/endocrinology within the breast
    • Miller W. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 6 (1999) 187-195
    • (1999) Endocr Relat Cancer , vol.6 , pp. 187-195
    • Miller, W.1
  • 39
    • 0034982329 scopus 로고    scopus 로고
    • Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors
    • Bhatnagar A., Brodie A., Long B., Evans D., and Miller W. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 76 (2001) 199-202
    • (2001) J Steroid Biochem Mol Biol , vol.76 , pp. 199-202
    • Bhatnagar, A.1    Brodie, A.2    Long, B.3    Evans, D.4    Miller, W.5
  • 40
    • 22744437908 scopus 로고    scopus 로고
    • Letrozole in the treatment of breast cancer
    • Mouridsen H., and Bhatnagar A. Letrozole in the treatment of breast cancer. Expert Opin Pharmacother 6 (2005) 1389-1399
    • (2005) Expert Opin Pharmacother , vol.6 , pp. 1389-1399
    • Mouridsen, H.1    Bhatnagar, A.2
  • 41
    • 0027167698 scopus 로고
    • Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds
    • Furet P., Batzl C., Bhatnagar A., Francotte E., Rihs G., and Lang M. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem 36 (1993) 1393-1400
    • (1993) J Med Chem , vol.36 , pp. 1393-1400
    • Furet, P.1    Batzl, C.2    Bhatnagar, A.3    Francotte, E.4    Rihs, G.5    Lang, M.6
  • 42
    • 0036467847 scopus 로고    scopus 로고
    • Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
    • Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 (2002) 751-757
    • (2002) J Clin Oncol , vol.20 , pp. 751-757
    • Geisler, J.1    Haynes, B.2    Anker, G.3    Dowsett, M.4    Lonning, P.5
  • 43
    • 34249321005 scopus 로고    scopus 로고
    • Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole
    • Abstract 103.
    • Geisler J. Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole. Breast Cancer Res Treat 100 Suppl 1 (2006) S23-S24 Abstract 103.
    • (2006) Breast Cancer Res Treat , vol.100 , Issue.SUPPL. 1
    • Geisler, J.1
  • 44
    • 33749505914 scopus 로고    scopus 로고
    • Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer
    • Abstract 552.
    • Dixon J., Renshaw L., Young O., et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 24 18S (2006) 15S Abstract 552.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S
    • Dixon, J.1    Renshaw, L.2    Young, O.3
  • 45
    • 0031123311 scopus 로고    scopus 로고
    • Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate
    • Lonning P., Geisler J., Johannessen D., et al. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. J Steroid Biochem Mol Biol 61 (1997) 255-260
    • (1997) J Steroid Biochem Mol Biol , vol.61 , pp. 255-260
    • Lonning, P.1    Geisler, J.2    Johannessen, D.3
  • 46
    • 7344242595 scopus 로고    scopus 로고
    • Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3)
    • Gershanovich M., Chaudri H., Campos D., et al. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 9 (1998) 639-645
    • (1998) Ann Oncol , vol.9 , pp. 639-645
    • Gershanovich, M.1    Chaudri, H.2    Campos, D.3
  • 48
    • 33947255652 scopus 로고    scopus 로고
    • The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
    • Jonat W., and Mundhenke C. The FACE trial: letrozole or anastrozole as initial adjuvant therapy?. Cancer Invest 25 (2007) 14-18
    • (2007) Cancer Invest , vol.25 , pp. 14-18
    • Jonat, W.1    Mundhenke, C.2
  • 49
    • 33750687260 scopus 로고    scopus 로고
    • Refining the postmenopausal breast cancer treatment paradigm: the FACE trial
    • Monnier A. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. Expert Rev Anticancer Ther 6 (2006) 1355-1359
    • (2006) Expert Rev Anticancer Ther , vol.6 , pp. 1355-1359
    • Monnier, A.1
  • 50
    • 14844358496 scopus 로고    scopus 로고
    • Clinical trial update: National Cancer Institute of Canada
    • Pritchard K., and Whelan T. Clinical trial update: National Cancer Institute of Canada. Breast Cancer Res 7 (2005) 48-51
    • (2005) Breast Cancer Res , vol.7 , pp. 48-51
    • Pritchard, K.1    Whelan, T.2
  • 51
    • 38949210774 scopus 로고    scopus 로고
    • Adjuvant therapy for early stage breast cancer (EBC): Distant disease-free survival (DDFS) as a predictor of overall survival (OS)
    • Abstract 583.
    • Melisko M., Lin A., and Rugo H. Adjuvant therapy for early stage breast cancer (EBC): Distant disease-free survival (DDFS) as a predictor of overall survival (OS). J Clin Oncol 25 18S (2007) 23S Abstract 583.
    • (2007) J Clin Oncol , vol.25 , Issue.18 S
    • Melisko, M.1    Lin, A.2    Rugo, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.